{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+regular+IV+infusion", "query": { "intervention": "insulin regular IV infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 106, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+regular+IV+infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T02:58:59.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01951716", "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Does the Vagus Nerve Mediate the Effects of Xenin-25" ], "interventions": [ { "name": "Graded Glucose Infusion with Placebo", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP Alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with xenin-25 alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP plus xenin-25", "type": "DRUG" }, { "name": "Meal Tolerance Test with Placebo", "type": "DRUG" }, { "name": "Meal Tolerance Test with xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951716" }, { "nct_id": "NCT00005889", "title": "Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infant, Low Birth Weight", "Hyperglycemia" ], "interventions": [ { "name": "alanine", "type": "DRUG" }, { "name": "amino acids", "type": "DRUG" }, { "name": "glucagon", "type": "DRUG" }, { "name": "glucose", "type": "DRUG" }, { "name": "glutamine", "type": "DRUG" }, { "name": "glycerol", "type": "DRUG" }, { "name": "insulin", "type": "DRUG" }, { "name": "leucine", "type": "DRUG" }, { "name": "lipids", "type": "DRUG" }, { "name": "urea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Center for Research Resources (NCRR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Days", "maximum_age": "6 Days", "sex": "ALL", "summary": "4 Days to 6 Days" }, "enrollment_count": 96, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005889" }, { "nct_id": "NCT06412497", "title": "MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia", "Acquired Amegakaryocytic Thrombocytopenia", "Acquired Pure Red Cell Aplasia", "Paroxysmal Nocturnal Hemoglobinuria" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Post-Transplant G-CSF", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "0 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2024-06-05", "completion_date": "2036-05-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06412497" }, { "nct_id": "NCT06883344", "title": "Automated Insulin for Management of Intrapartum Glycemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes (T1D)", "Pregnancy", "Pre-Gestational Diabetes" ], "interventions": [ { "name": "Automated insulin delivery (AID) system", "type": "DEVICE" }, { "name": "Intravenous (IV) insulin", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 150, "start_date": "2025-12-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06883344" }, { "nct_id": "NCT02054429", "title": "Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ischemic Stroke" ], "interventions": [ { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2013-01", "completion_date": "2016-12-31", "has_results": false, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02054429" }, { "nct_id": "NCT02103283", "title": "A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Teprotumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-10", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 3, "location_summary": "Beverly Hills, California • St. Petersburg, Florida • Omaha, Nebraska", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02103283" }, { "nct_id": "NCT02045368", "title": "Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Brain Cancer", "Gastrointestinal Cancers", "Genitourinary Cancers", "Gynecologic Cancers", "Head and Neck Cancers", "Melanoma", "Thoracic Cancers" ], "interventions": [ { "name": "IGF-Methotrexate conjugate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGF Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2014-01-28", "completion_date": "2016-09-30", "has_results": false, "last_update_posted_date": "2019-08-22", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02045368" }, { "nct_id": "NCT01498952", "title": "MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable or Metastatic Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "MEDI-573 (1 of 3 doses)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2012-01-17", "completion_date": "2013-04-09", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 3, "location_summary": "Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada", "locations": [ { "city": "Oxnard", "state": "California" }, { "city": "Golden Springs", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01498952" }, { "nct_id": "NCT03175978", "title": "IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic", "Anemia, Refractory, With Excess of Blasts" ], "interventions": [ { "name": "IGF/MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGF Oncology, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-02-21", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Saint Paul, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175978" }, { "nct_id": "NCT02371226", "title": "Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucopolysaccharidosis I" ], "interventions": [ { "name": "AGT-181 (HIRMAb-IDUA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArmaGen, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-07", "completion_date": "2017-02-01", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-09-17T02:58:59.504Z", "location_count": 6, "location_summary": "Oakland, California • Orange, California • Decatur, Georgia + 3 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02371226" } ] }